| Ms Elaine Alice Cong, MD | |
|
180 Engle St, Englewood, NJ 07631-2507 | |
| (201) 567-2050 | |
| (201) 567-5070 |
| Full Name | Ms Elaine Alice Cong |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 15 Years |
| Location | 180 Engle St, Englewood, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710120944 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 25MA09678600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Englewood Hospital And Medical Center | Englewood, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Associates Of Englewood Pc | 1355512252 | 519 |
News Archive
A new multidisciplinary study from Australia, published in the open-access journal mBio, shows that three compounds used to treat cystic fibrosis, dry eye, and a specific medical dye may lead to future strategies for the treatment of coronavirus disease (COVID-19).
Researchers at Moffitt Cancer Center and colleagues have found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. They also found that standard health-related quality-of-life survey tools used to elicit answers from teens with cancer did not accurately reflect these concerns. Parents, who often answer survey questions as proxies, often inaccurately relayed their child's reproductive concerns.
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).
CIGNA (NYSE:CI) today announced the initial results of its multi-year strategy that places an entirely new focus on improving customers' experience. The effort has led to an improvement in customer understanding of their benefits in excess of 100 percent, a 50 percent reduction in the number of printed materials customers receive, and the use of simpler language that doesn't rely on insurance jargon. It also led CIGNA to become the first in its industry to offer 24 hour-a-day, seven day-a-week customer service.
› Verified 7 days ago
| Entity Name | Medical Associates Of Englewood Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952681918 PECOS PAC ID: 1355512252 Enrollment ID: O20110927000020 |
News Archive
A new multidisciplinary study from Australia, published in the open-access journal mBio, shows that three compounds used to treat cystic fibrosis, dry eye, and a specific medical dye may lead to future strategies for the treatment of coronavirus disease (COVID-19).
Researchers at Moffitt Cancer Center and colleagues have found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. They also found that standard health-related quality-of-life survey tools used to elicit answers from teens with cancer did not accurately reflect these concerns. Parents, who often answer survey questions as proxies, often inaccurately relayed their child's reproductive concerns.
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).
CIGNA (NYSE:CI) today announced the initial results of its multi-year strategy that places an entirely new focus on improving customers' experience. The effort has led to an improvement in customer understanding of their benefits in excess of 100 percent, a 50 percent reduction in the number of printed materials customers receive, and the use of simpler language that doesn't rely on insurance jargon. It also led CIGNA to become the first in its industry to offer 24 hour-a-day, seven day-a-week customer service.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Elaine Alice Cong, MD 180 Engle St, Englewood, NJ 07631-2507 Ph: (201) 567-2050 | Ms Elaine Alice Cong, MD 180 Engle St, Englewood, NJ 07631-2507 Ph: (201) 567-2050 |
News Archive
A new multidisciplinary study from Australia, published in the open-access journal mBio, shows that three compounds used to treat cystic fibrosis, dry eye, and a specific medical dye may lead to future strategies for the treatment of coronavirus disease (COVID-19).
Researchers at Moffitt Cancer Center and colleagues have found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. They also found that standard health-related quality-of-life survey tools used to elicit answers from teens with cancer did not accurately reflect these concerns. Parents, who often answer survey questions as proxies, often inaccurately relayed their child's reproductive concerns.
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).
CIGNA (NYSE:CI) today announced the initial results of its multi-year strategy that places an entirely new focus on improving customers' experience. The effort has led to an improvement in customer understanding of their benefits in excess of 100 percent, a 50 percent reduction in the number of printed materials customers receive, and the use of simpler language that doesn't rely on insurance jargon. It also led CIGNA to become the first in its industry to offer 24 hour-a-day, seven day-a-week customer service.
› Verified 7 days ago
Dr. Annalisa Pastore, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 60 Grand Ave, Englewood, NJ 07631 Phone: 201-308-5326 | |
Deborah A Fein, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 177 N Dean St, Englewood, NJ 07631 Phone: 201-567-0446 | |
Jeffrey Martin Mitchel, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 370 Grand Ave, Englewood, NJ 07631 Phone: 201-567-7576 Fax: 201-567-8628 | |
Dennis Katechis, DO Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 177 N Dean St, Suite 100, Englewood, NJ 07631 Phone: 201-816-2508 Fax: 201-569-6111 | |
Dr. Ebben Will Smith, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 370 Grand Ave, Suite 102, Englewood, NJ 07631 Phone: 201-567-3370 | |
Dr. Ma. Conchitina Manas Fojas, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 229 Engle St, Englewood, NJ 07631 Phone: 201-567-5385 | |
Steven J Weisholtz, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 25 Rockwood Pl, Englewood, NJ 07631 Phone: 201-568-8130 Fax: 201-568-2450 |